122 related articles for article (PubMed ID: 24488322)
1. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
Becerra CR; Salazar R; Garcia-Carbonero R; Thomas AL; Vázquez-Mazón FJ; Cassidy J; Maughan T; Castillo MG; Iveson T; Yin D; Green S; Bergsland EK
Cancer Chemother Pharmacol; 2014 Apr; 73(4):695-702. PubMed ID: 24488322
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
de Bono JS; Piulats JM; Pandha HS; Petrylak DP; Saad F; Aparicio LM; Sandhu SK; Fong P; Gillessen S; Hudes GR; Wang T; Scranton J; Pollak MN
Clin Cancer Res; 2014 Apr; 20(7):1925-34. PubMed ID: 24536060
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
7. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
8. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
9. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
Haluska P; Worden F; Olmos D; Yin D; Schteingart D; Batzel GN; Paccagnella ML; de Bono JS; Gualberto A; Hammer GD
Cancer Chemother Pharmacol; 2010 Mar; 65(4):765-73. PubMed ID: 19649631
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Rothenberg ML; LaFleur B; Levy DE; Washington MK; Morgan-Meadows SL; Ramanathan RK; Berlin JD; Benson AB; Coffey RJ
J Clin Oncol; 2005 Dec; 23(36):9265-74. PubMed ID: 16361624
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
Karp DD; Paz-Ares LG; Novello S; Haluska P; Garland L; Cardenal F; Blakely LJ; Eisenberg PD; Langer CJ; Blumenschein G; Johnson FM; Green S; Gualberto A
J Clin Oncol; 2009 May; 27(15):2516-22. PubMed ID: 19380445
[TBL] [Abstract][Full Text] [Related]
15. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
16. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM
Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.
Ducreux M; Bennouna J; Adenis A; Conroy T; Lièvre A; Portales F; Jeanes J; Li L; Romano A
Cancer Chemother Pharmacol; 2017 Jan; 79(1):9-16. PubMed ID: 27866244
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
19. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.
Lin EH; Lenz HJ; Saleh MN; Mackenzie MJ; Knost JA; Pathiraja K; Langdon RB; Yao SL; Lu BD
Cancer Med; 2014 Aug; 3(4):988-97. PubMed ID: 24905030
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
